RxDoctor Payments Data

Maureen Offiah, MD

Dermatology · Hattiesburg, MSNPI 1760896195

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by LEO Pharma Inc. at 31.6% of the total. 2025 is the largest year on record at $254,407, more than ten times the $993 reported in 2019. Among dermatology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$274,515in general payments, 2019–2025

Across 1,001 payments — averaging $274.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LEO Pharma Inc.$87K
  • Arcutis Biotherapeutics, Inc.$79K
  • Amgen$40K
  • Kowa Pharmaceuticals America, Inc.$26K
  • E.r. Squibb & Sons, L.L.C.$13K
  • UCB, Inc.$10K
  • plus $19K from 32 others

What the payments were for

  • Consulting fees$98,13336%
  • Speaking & faculty fees$126,16346%
  • Travel & lodging$30,06111%
  • Food & beverage$19,7787%
  • Education$3800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$274,515 in reported general payments places this provider in the 95th percentile of 78 dermatology providers in Mississippi.

See all dermatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$405,374
Medicare patients
769
Services billed
4,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab16$166,962
Dupixent PenDupilumab34$140,291
OtezlaApremilast22$114,800
Tacrolimus411$53,322
Ketoconazole739$12,357
Acitretin16$12,156
Mupirocin1,033$8,358
Clobetasol Propionate208$7,471
Ammonium Lactate367$7,290
Gentamicin Sulfate126$6,802
Clindamycin Phosphate99$4,410
Triamcinolone Acetonide306$4,401
Fluocinonide101$4,117
Doxycycline Monohydrate125$3,749
Hydrocortisone433$3,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$40,449$114,80022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 78 dermatology providers in Mississippi.

Other dermatology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →